Despite market challenges due to the COVID-19 pandemic, 2020 was a game-changing year for enabling technology for orthopedic surgery with robotics hitting an inflection point in acceptance, with record placements in Q420, and enabling technology across the entire continuum of care making significant inroads.

In Q420, MAKO* robot demand drove much of the 12.3% growth in Stryker’s* US Ortho Other segment. In 2020, MAKO’s installed base grew by 33%, and in Q420 hit a milestone of > 100 system installations at major teaching institutions, ASCs and in competitive accounts in the quarter. In fact, according to the Company, MAKO is now available in ~50% of fellowship programs at teaching institutions in US, as well as some in Europe, which will help the transition to standard of care. Stryker noted that new market entrants (Zimmer Biomet’s* ROSA*, Smith & Nephew’s* CORI* and DePuy Synthes’* VELYS*) have not slowed MAKO momentum.

Among the many topics covered in the comprehensive Q420/FY20 CAS Ortho Market Recap* are:

COVID-19 threw a curveball to spine and orthopedic implant companies in 2020 with the downturn in elective procedures, but one area that continued to make inroads was enabling technologies. Given increasing advances and expanding adoption of these technologies, even during uncertain times, SmartTRAK highlights some significant trends to watch in 2021, including:

1. Flexible Business Models
Companies with robots (Stryker*, MAKO*, Zimmer Biomet*, ROSA*, Smith & Nephew*, NAVIO*/CORI*, Medtronic*, Mazor X*, Globus*, Excelsius GPS) continued to grow at above-market growth in 2020. Record-breaking robotic and navigation system placements in Q3 and Q420 bode well for ...

Healthy growth closes out Q420 as the trauma segment recovers in the second half of the year hitting pre-COVID levels.

Despite the rise in COVID cases during Q4, the Trauma Market fared well resulting in positive YoY revenue gains that represented healthy, pre-COVID level volumes. Trauma players cited another quarter of healthy trauma growth, as the second half of the year ended on an upswing (+5.6% vs. H219). Top US market leaders, DePuy Synthes (49.4% Q420 US share), Stryker (27.3%) and Smith & Nephew (9.8%) all reported improved sequential gains.

Among the many topics covered in the comprehensive Q420/FY20 Trauma Market Recap* are:

Surge in COVID-19 Wipes Out Some Procedural Recovery

The surge of COVID-19 cases in Q420 likely brought on by holiday gatherings threatened to wash away the beginning of elective procedure recovery in Q3. In some regions of the US, healthcare facilities once again found themselves underwater as they struggled to care for COVID patients. OUS, Britain and other countries continued to face shutdowns and delay of non-urgent procedures.

Among the many topics covered in the comprehensive Q420/FY20 Total Joints Market Recap* are:

Facing the prevailing headwinds of the pandemic, the MedTech industry presses on with product innovation and plans for the future. SmartTRAK reports daily on the challenges still ahead, covering all aspects of the Orthopedic market: Extremities, OrthoBio, Spine, Computer Assisted Surgery, Total Joints, Trauma, Soft Tissue Fixation and EU Extremities and Trauma.

The following is just a small sampling of the Orthopedic updates from around the world compiled, reviewed and posted in real time last week by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry.

From the global pandemic, shifts in site of care and technologies of interest, to the shift of procedures, these are some of the trends to watch in 2021

In 2020, monitoring the effects that COVID-19 had on joint replacement market quickly dominated the collective consciousness. And as we enter 2021, it is sure to remain top of mind but other trends are worth watching as well. From the shift in site-of-care to technologies of interest, SmartTRAK outlines some of the developments in the joint replacement market.

Among the many things to watch for in 2021 that are included in detail in this Market Outlook analysis article, written by Lisa Mahan, SmartTRAK's VP of Orthopedics, are:

• Expect Early Market Stops and Starts, Ups and Downs - After the initial wave of COVID-19 in March 2020, elective surgical procedures returned in Q2 and Q320 along with market recovery. However, a rising wave of COVID cases leading into the new year precipitated another round of shutdowns in different regions across the US ...
  
  

As companies ride the latest wave of COVID-19, SmartTRAK predicts the trends and technologies that will continue to advance the trauma industry in 2021 and 2022.

Trend #1: Procedures Return to Near-Normal Levels in 2021

After the first swell of COVID-19 this past March, elective surgeries took a major hit. As most procedures were postponed during this phase of the pandemic, the trauma segment was impacted to a lesser extent. In early 2020, trauma surgeons reported seeing definite decreases in volumes due to stay-at-home orders, with polytrauma being almost negligible in certain US cities. Geriatric fractures also decreased, but to a lesser extent according to the OTA COVID-19 Webinar discussion. Despite the decrease, surgeons treated the majority of trauma fracture fixation procedures and provided conservative treatment in only a small portion of patients who were in facilities or areas heavily impacted by COVID-19.

We are pleased to announce that Andy Knapik has joined the team at SmartTRAK as Senior Analyst, Soft Tissue Fixation and Arthroscopic Technologies. Andy has 20+ years’ experience in US and International sales and marketing for the orthopedics and sports medicine markets, including 12 years at Smith & Nephew.

Meet Andy Knapik:

What is your role with SmartTRAK? As Senior Analyst for Soft Tissue Fixation and Arthroscopic Technologies, I am currently developing and supporting the Arthroscopic Technologies module, which is new to SmartTRAK, as well as the Sports Medicine Repair module.

What do you like about SmartTRAK? I love the depth and range of experience of all of the analysts. There is a lot of industry knowledge that we can offer customers, and it’s really impressive to me.

What is something special or unique that you bring to SmartTRAK subscribers? I have 20 years of experience in orthopedics working with just about every product that an orthopedist would use from sports medicine and arthroscopy, to trauma and reconstruction. I have also worked in diverse geographies, working in both the US market and internationally in both established as well as emerging markets. So even though my current specialty lies in sports medicine and arthroscopy, there is quite a bit of cross over in general orthopedics that I am able to discuss.

Although the COVID-19 roller coaster was a tough ride in Q220, Soft Tissue Fixation was stepping out and looking good in Q320

When an unpredictable COVID-19 roller coaster hit the tracks, companies saw revenue plummet in Q220 as stay-at-home orders were implemented (mid-March) and elective surgeries were canceled or postponed indefinitely. The impact of COVID-19 that forced government-imposed restrictions was felt throughout the 2

With restrictions lifted during Q320, the trauma segment rebounded from the prior quarter as procedural volumes increased and revenues hit pre-COVID levels.

In the absence of strict COVID restrictions, the jump ball went to the return of healthy trauma volumes during Q320. Major players cited quarterly growth in line with previous years. Q320 picked up the pace with the US Trauma Market leading the charge, up +4.6%, while the EU and ROW declined.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Trauma Market Recap* are: